Delivery of phosphodiester oligonucleotides: can DOTAP/DOPE liposomes do the trick?

K Remaut1, B Lucas, K Braeckmans

  • 1Laboratory of General Biochemistry and Physical Pharmacy, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium.

Biochemistry
|February 8, 2006
PubMed

Insights

DOTAP/DOPE liposomes fail to deliver phosphodiester oligonucleotides (PO-ONs) due to rapid degradation after endosomal escape. They are more suitable for delivering nuclease-resistant phosphothioate oligonucleotides (PS-ONs), though cellular export limits their nuclear presence.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Delivery Systems

Background:

  • Antisense therapy aims to deliver oligonucleotides (ONs) to modulate gene expression.
  • Phosphodiester ONs (PO-ONs) are attractive but challenging to deliver effectively.
  • Cationic liposomes like DOTAP/DOPE often fail with PO-ONs but succeed with modified ONs (PS-ONs).

Purpose of the Study:

  • To elucidate the cell biological behavior of PO- and phosphothioate ONs (PS-ONs) delivered by DOTAP/DOPE liposomes.
  • To understand why DOTAP/DOPE liposomes are ineffective for PO-ON delivery in antisense therapy.
  • To compare the cellular fate and activity of PO-ONs versus PS-ONs using DOTAP/DOPE liposomes.

Main Methods:

  • Utilized fluorescence correlation spectroscopy (FCS) to study ON behavior within cells.
  • Employed confocal laser scanning microscopy (CLSM) for visualizing ON and liposome interactions.
  • Investigated the cellular uptake, endosomal escape, and degradation pathways of delivered ONs.

Main Results:

  • DOTAP/DOPE liposomes release naked PO-ONs during endosomal escape, leading to their rapid degradation.
  • PS-ONs, upon release, are resistant to degradation, forming an active pool within cells.
  • Cellular export mechanisms limit the nuclear accumulation of intact PS-ONs to approximately 8 hours.

Conclusions:

  • DOTAP/DOPE liposomes are unsuitable for delivering PO-ONs due to premature release and degradation.
  • These liposomes are primarily effective for delivering nuclease-resistant ONs like PS-ONs.
  • Future carriers should prevent PO-ON release until target mRNA interaction to enhance antisense therapy efficacy.